NAPROXEN Rx-TO-OTC SWITCH APPLICATION FINAL FDA REVIEW STAGE
This article was originally published in The Tan Sheet
NAPROXEN Rx-TO-OTC SWITCH APPLICATION FINAL FDA REVIEW STAGE is understood to include a careful once-over of the key issues by the FDA commissioner's office. Recognizing the sensitivities of an FDA override of the rejection of the naproxen sodium switch by a joint advisory committee, FDA Commissioner David Kessler has asked that "option" papers be prepared to relate the concerns raised by the committee. The decision to reconsider some of the implications of the naproxen switch is a reasonable precaution given the high-profile nature of the application and the 7-4 rejection of the switch at a joint meeting of FDA's Nonprescription Drugs and Arthritis Advisory Committees in June ("The Tan Sheet" June 7, pp. 1-6). Some of the concerns raised by committee members apparently have been worked out by FDA and the switch application sponsors, Syntex and Procter & Gamble. In a presentation to the Nonprescription Drugs and Arthritis Advisory Committees in September, Office of OTC Drug Evaluation Director Michael Weintraub said that Syntex had agreed to reduce its proposed maximum daily dose of OTC naproxen sodium from 800 mg to 600 mg and that the dosing interval would be lengthened from one tablet every six-to-12 hours to one tablet every eight-to-12 hours ("The Tan Sheet" Sept. 13, p. 9).
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC